Cell Signaling Technology

Product Pathways - NF-kB Signaling

SignalSilence® NDP52 siRNA I #8964

Applications Reactivity
Transfection H (Mk)

Reactivity Key:  H=Human  Mk=Monkey
Species cross-reactivity is determined by western blot. Species enclosed in parentheses are predicted to react based on 100% sequence homology.

Western Blotting

Western Blotting

Western blot analysis of extracts from HeLa cells, transfected with 100 nM SignalSilence® Control siRNA (Unconjugated) #6568 (-), SignalSilence® NDP52 siRNA I (+), or SignalSilence® NDP52 siRNA II #9000 (+), using NDP52 Antibody #9036 (upper) or β-Actin (D6A8) Rabbit mAb #8457 (lower). The NDP52 Antibody confirms silencing of NDP52 expression, while the β-Actin (D6A8) Rabbit mAb is used as a loading control.

Description

SignalSilence® NDP52 siRNA I from Cell Signaling Technology (CST) allows the researcher to specifically inhibit NDP52 expression using RNA interference, a method whereby gene expression can be selectively silenced through the delivery of double stranded RNA molecules into the cell. All SignalSilence® siRNA products from CST are rigorously tested in-house and have been shown to reduce target protein expression by western analysis.

Quality Control

Oligonucleotide synthesis is monitored base by base through trityl analysis to ensure appropriate coupling efficiency. The oligo is subsequently purified by affinity-solid phase extraction. The annealed RNA duplex is further analyzed by mass spectrometry to verify the exact composition of the duplex. Each lot is compared to the previous lot by mass spectrometry to ensure maximum lot-to-lot consistency.

Directions for Use

CST recommends transfection with 100 nM SignalSilence® NDP52 siRNA I 48 to 72 hours prior to cell lysis. For transfection procedure, follow protocol provided by the transfection reagent manufacturer. Please feel free to contact CST with any questions on use. Each vial contains the equivalent of 100 transfections, which corresponds to a final siRNA concentration of 100 nM per transfection in a 24-well plate with a total volume of 300 μl per well.

Background

NDP52 (CALCOCO2) is ubiquitously expressed and composed of an amino-terminal SKICH domain, followed by a coiled-coil domain, and two zinc finger domains (1). It has recently been reported to act as an autophagy receptor that binds cytosolic ubiquitinated bacteria, leading to autophagy activation and pathogen clearance (1-3). NDP52 binds ubiquitin through its zinc finger domain and simultaneously binds LC3, which directs the bacteria into autophagosomes. In addition, NDP52 interacts with Nap1 and SINTBAD to recruit TBK1 to ubiquitinated bacteria (1).

  1. Thurston, T.L. et al. (2009) Nat Immunol 10, 1215-21.
  2. Cemma, M. et al. (2011) Autophagy 7, 341-5.
  3. Mostowy, S. et al. (2011) J Biol Chem 286, 26987-95.

Application References

Have you published research involving the use of our products? If so we'd love to hear about it. Please let us know!

Companion Products

Limited Use Label License, RNA interference: This product is licensed under European Patent 1144623 and foreign equivalents from Ribopharma AG, Kulmbach, Germany and is provided only for use in non-commercial research specifically excluding use (a) in drug discovery or drug development, including target identification or target validation, by or on behalf of a commercial entity, (b) for contract research or commercial screening services, (c) for the production or manufacture of siRNA-related products for sale, or (d) for the generation of commercial databases for sale to Third Parties. Information about licenses for these and other commercial uses is available from Ribopharma AG, Fritz-Hornschuch-Str. 9, D-95326 Kulmbach, Germany.

For Research Use Only. Not For Use In Diagnostic Procedures.

Products